Atlas Trials

A Study to Learn About the Outcomes Between Study Medicines, Enzalutamide and Darolutamide Among Men With Metastatic Castration Sensitive Prostate Cancer (mCSPC)

Clinical trial NCT07779590 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07779590
Sponsor
Pfizer
Status
NOT_YET_RECRUITING
Study type
OBSERVATIONAL
Metastatic Castration Sensitive Prostate Cancer (mCSPC)
Start date
2026-09-01
Primary completion
2026-11-15
Enrollment
4700

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.